Valiant Laboratories Balance Sheet
- Market cap
- ₹657 crore
- P/E
- 22.5
- P/B
- 2.85
- ROE
- 14.5%
- Dividend yield
- 1.20%
- 52-week range
- ₹87.08 – ₹163.27
As of FY25, Valiant Laboratories had total assets of ₹427 crore and borrowings of ₹78.82 crore, against shareholders' equity of ₹416 crore — a debt-to-equity ratio of 0.35.
Valiant Laboratories balance sheet
As at each financial year end, newest first. H1 = half-year.
| Item | FY25 |
|---|---|
| Equity capital | 120 |
| Reserves | 296 |
| Borrowings | 78.82 |
| Other liabilities | 52.55 |
| Total liabilities | 427 |
| Fixed assets | 230 |
| Capital work in progress | 45 |
| Investments | 98.53 |
| Other assets | 98.53 |
| Total assets | 427 |
Balance sheet ratios
- Debt to equity
- 0.35
- Book value per share
- ₹42.44
Source: Company filings (consolidated), in ₹ crore. Data as of 9 October 2026. How this data is compiled.
Valiant Laboratories balance sheet — frequently asked questions
What is the total debt of Valiant Laboratories?
Valiant Laboratories reported borrowings of ₹78.82 crore as of FY25.
What is Valiant Laboratories' debt-to-equity ratio?
Based on the FY25 balance sheet, Valiant Laboratories' debt-to-equity ratio is 0.35 — borrowings of ₹78.82 crore against equity capital and reserves of ₹416 crore.
What are Valiant Laboratories' total assets?
Valiant Laboratories' total assets were ₹427 crore as of FY25, including fixed assets of ₹230 crore and investments of ₹98.53 crore.
What is the book value per share of Valiant Laboratories?
The book value per share of Valiant Laboratories is ₹42.44, based on the latest reported balance sheet.
Same Data For Peers
Trade Valiant Laboratories With ATS
Track VALIANTLAB live and place orders from the Pocket app or the Pocket Web terminal with an ATS trading and demat account.
Figures are for information only and are not investment advice or a recommendation to buy, sell or hold any security. Investments in securities are subject to market risks; read all related documents carefully before investing.